This activity is intended for primary care physicians. If you would like the full audio-visual presentation then please click here.

After completing this activity, participants should be able to:

• Discuss the pathophysiology of childhood asthma with emphasis on peripheral airway disease and heterogeneity of the disease.
• Discuss the current management of asthma in children with focus on tailoring asthma care for each patient.
• Identify limitations of our preferred medication steps in asthma management in children.
• Summarize reasons that alternative treatment steps, specifically the use of a leukotriene receptor antagonist, could provide benefit in overall asthma management for children.

National Jewish Medical and Research Center is accredited by the ACCME to provide continuing medical education for physicians.

National Jewish Medical and Research Center designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Erwin Gelfand, MD
Chair, Department of Pediatrics
National Jewish Medical and Research Center
Professor of Pediatrics and Immunology
University of Colorado Health Sciences Center

Joseph Spahn, MD
Associate Professor, Department of Pediatrics
Director, Immunopharmacology Lab, Division of Clinical Pharmacology
Director, Pediatric Allergy/Immunology Fellowship Program
National Jewish Medical and Research Center

Associate Professor of Pediatrics,
University of Colorado Health Sciences Center

Stanley Szefler, MD
Professor, Department of Pediatrics
HelenWohlberg and Herman Lambert Chair in Pharmacokinetics,
Head of Pediatric Clinical Pharmacology,
Director of the Pediatric Clinical Trials Center, and Co-Director of theWeinberg Clinical Research Unit
National Jewish Medical and Research CenterProfessor of Pediatrics and Pharmacology,
University of Colorado Health Sciences Center

Disclosure Information Listed for CME Approval Committee and Program Faculty

All faculty in a position to control the content of this activity are expected to disclose any or no significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.

Key
± Research Grant
^ Consultant
~ Speakers' Bureau
§ Other (eg clinical study)

David Beuther, MD
± Merck & Co., Inc.

Mark Boguniewicz, MD
± § Novartis
± Astellas Pharma, Inc., Sinclair Pharma, PLC.
^ Alza Corporation, Chester Valley Pharmaceuticals, Inc.

Ronina Covar, MD
^ AstraZeneca, Merck & Co., Inc.
± AstraZeneca, Ross Products/Abbott Laboratories

Stephen K. Frankel, MD
Has no significant financial interest to report

Erwin Gelfand, MD
± Merck, Inc., Novartis
^ Novartis, sanofi-aventis, Schering, Teva
~ Merck, Inc., Novartis

Allidah Hicks, RN, MS
Has no significant financial interest to report

Harold Nelson, MD
National Jewish Medical and Research Center
^ Curalogic, Dey Laboratories, Dynavax Technologies, Genentech, GlaxoSmithKline, Johnson & Johnson, Novartis, Schering Plough (Integrated Therapeutics Group)
~ AstraZeneca, GlaxoSmithKline
± Boehringer, Clinical Therapeutics, Genentech, MediciNova, Inc., Sepracor, Inc., Novartis, Schering Plough (Integrated Therapeutics Group), Teva Pharmaceutical Industries Ltd.,Wyeth

Joseph Spahn, MD
± AstraZeneca, Merck, Inc.
^ AstraZeneca, GlaxoSmithKline, Merck, Inc.

Stanley Szefler, MD
^ AstraZeneca, Genentech, GlaxoSmithKline, Merck,Inc., Novartis, sanofi-aventis

Richard W. Weber, MD
^ AstraZeneca, Genentech/Novartis
˜ AstraZeneca, Genentech/Novartis, GlaxoSmithKline
± Eli Lilly and Company, GlaxoSmithKline, MannKind Corporation, Pfizer, Inc.

This activity is supported by an educational grant from Merck, Inc.